Simon Westbrook
Founder & Chief Scientific Officer Levicept
Simon has a strong track record of innovation and delivery of drug development programmes with 30 years of drug discovery and development experience, including 15 years at Pfizer Sandwich UK. Simon has played pivotal roles in progressing novel, successful projects from conception of idea to delivery of clinical data. Simon is the named inventor on numerous patents, including p75NTR-Fc for the treatment of pain. He was a team member of four programmes that achieved positive readout in proof-of-concept phase II clinical trials and SGLT-2 inhibitor STEGLATROM which is marketed for treatment of Type II diabetes.
Seminars
Wednesday 27th January 2027
Harnessing Neurotrophin-3 Biology to Address the Underlying Drivers of Chronic Pain
2:00 pm
- Exploring how excess neurotrophin-3 (NT-3) signalling contributes to chronic pain sensitisation and functional impairment across osteoarthritis and other painful conditions
- Reviewing Phase II clinical data for LEVI-04, a first-in-class p75NTR-Fc fusion protein, demonstrating significant improvements in pain, function and stiffness in patients with osteoarthritis
- Evaluating a differentiated approach to neurotrophin modulation that seeks to deliver meaningful analgesia while avoiding the joint safety concerns historically associated with anti-NGF therapies
- Assessing the future potential of NT-3 inhibition across osteoarthritis, musculoskeletal disorders and broader chronic pain indications
